This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.
Neogen (NEOG) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Neogen (NEOG) delivers core growth in both the Food Safety and Animal Safety segments amid macroeconomic headwinds in the third quarter.
Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials
by Zacks Equity Research
Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.
UnitedHealth (UNH) Arm to Reduce Prior Authorization Time
by Zacks Equity Research
UnitedHealth's (UNH) UnitedHealthcare business to lower the use of prior authorization process or preauthorization by almost 20%.
Tenet Healthcare (THC) Jumps 14.9% YTD: More Growth Ahead?
by Zacks Equity Research
Tenet Healthcare's (THC) focus on boosting USPI's network is positioning the company for expedited growth.
QIAGEN (QGEN) QIAxcel Connect Gets Red Dot Design Award
by Zacks Equity Research
QIAGEN (QGEN) QIAxcel Connect automates the analysis of the size and quality of isolated DNA and RNA.
Teleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays
by Zacks Equity Research
Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.
Thermo Fisher (TMO) Partners With ArsenalBio for Cancer R&D
by Zacks Equity Research
Thermo Fisher's (TMO) latest collaboration with ArsenalBio supports the latter's clinical manufacturing of autologous T-cell therapies for advanced cancer treatment.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its planned geographic expansion.
Illumina (ILMN) to Enable Tertiary Analysis With New Launch
by Zacks Equity Research
Illumina's (ILMN) Connected Software is an end-to-end software system that standardizes analysis tools and connects data across the genomics workflow.
Reasons to Add The Cooper Companies (COO) to Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
Surmodics (SRDX) Gets FDA's Formal Feedback About SurVeil DCB
by Zacks Equity Research
Surmodics' (SRDX) receipt of the FDA's positive formal feedback regarding its PMA application for the SurVeil DCB looks promising.
Masimo (MASI) Unveils Freedom Smartwatch With Privacy Switch
by Zacks Equity Research
Masimo's (MASI) newest wearable product seamlessly integrates continuous health tracking technology and breakthrough features.
Here's Why You Should Retain Avantor (AVTR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Avantor's (AVTR) strong product portfolio.
Insulet (PODD) Benefits From Omnipod 5 Launch, Expansion
by Zacks Equity Research
Insulet (PODD) witnesses continued uptake of Omnipod through the U.S. pharmacy channel.
NextGen's (NXGN) New Cloud-Based Solution to Improve Workflow
by Zacks Equity Research
NextGen's (NXGN) latest product is expected to simplify connectivity for healthcare providers, thereby solving clinical data exchange challenges.
CVS Health (CVS) Nears Completion of $8B SGFY Acquisition
by Zacks Equity Research
According to CVS Health (CVS), Signify Health, a leading healthcare platform, is set to play a critical role in advancing its healthcare services strategy.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on solid fourth-quarter 2022 performance and its strategies to accelerate growth.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution during fiscal Q2.
Elevance (ELV) Arm to Bring Virtual-First Plans to Georgia
by Zacks Equity Research
The cocktail of virtual and in-person options from Elevance Health's (ELV) part of the Anthem family of brands is expected to enrich members' health experience.
Thermo Fisher (TMO) Opens New Cell Therapy Facility at UCSF
by Zacks Equity Research
Thermo Fisher's (TMO) new cell therapy facility at UCSF is likely to accelerate the development of advanced therapies.
Quest Diagnostics (DGX) Introduces New Post-COVID-19 Panels
by Zacks Equity Research
Quest Diagnostics' (DGX) latest panels provide consumers a deeper look into their health, helping to prepare them for meaningful discussions with their healthcare providers
Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales decline reflects lower demand for COVID-19 services.
Here's Why You Should Retain Inogen (INGN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Abbott's (ABT) CardioMEMS Favors Heart Failure Management
by Zacks Equity Research
Abbott (ABT) announces key findings from meta-analysis, which shows remote pressure monitoring to be a life-extending option among heart failure patients.